Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Leerink Partnrs cut their Q2 2025 EPS estimates for shares of Gilead Sciences in a research note issued to investors on Monday, July 14th. Leerink Partnrs analyst D. Graybosch now forecasts that the biopharmaceutical company will post earnings of $1.91 per share for the quarter, down from their prior forecast of $2.25. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Leerink Partnrs also issued estimates for Gilead Sciences' FY2025 earnings at $8.15 EPS, FY2026 earnings at $8.99 EPS, FY2027 earnings at $10.55 EPS, FY2028 earnings at $11.16 EPS and FY2029 earnings at $12.22 EPS.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The business's quarterly revenue was down .3% compared to the same quarter last year.
A number of other equities analysts have also weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.
View Our Latest Analysis on Gilead Sciences
Gilead Sciences Stock Up 0.7%
GILD stock traded up $0.79 during trading on Wednesday, reaching $109.85. 3,957,440 shares of the stock were exchanged, compared to its average volume of 7,672,281. The firm's 50 day moving average is $108.15 and its 200 day moving average is $104.91. Gilead Sciences has a twelve month low of $70.33 and a twelve month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The firm has a market cap of $136.65 billion, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in Gilead Sciences in the 4th quarter valued at $1,789,254,000. Price T Rowe Associates Inc. MD boosted its holdings in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. FMR LLC boosted its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. Nuveen LLC bought a new position in Gilead Sciences in the 1st quarter valued at $620,415,000. Finally, GAMMA Investing LLC boosted its holdings in Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. 83.67% of the stock is owned by institutional investors.
Insider Transactions at Gilead Sciences
In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,000 shares of company stock worth $7,844,775. Insiders own 0.27% of the company's stock.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
